Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 11 of 13 · 376 total
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB issued a Final Written Decision finding all 27 challenged claims unpatentable based on obviousness over prior art (Racz, Fitz, Lee). The Board adopted the Petitioner's broad definition of POSA in the field of thermal ablation systems.
3D Diagnostix, Inc. v.Watson Guide IP, LLC
3D Diagnostix petitions the PTAB to invalidate 13 claims of Watson Guide IP’s dental guide patent, alleging lack of written description, indefiniteness, and obviousness over multiple prior‑art references.
Medela LLC et al. v.M.E.A.C. Engineering Ltd.
Medela and M.E.A.C. Engineering have settled their dispute over U.S. Patent 8,858,534 and jointly moved to terminate the pending inter partes review. The Board has not yet instituted the IPR, and the parties seek confidentiality for the settlement agreement.
Medela LLC et al. v.M.E.A.C. Engineering Ltd.
Medela and M.E.A.C. Engineering settled their IPR dispute over patent 8,858,534 B2. The Board terminated the proceeding before any trial, keeping the settlement confidential.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed has filed an IPR petition challenging 27 claims of Cleveland Medical Devices’ ’680 patent covering networked PAP therapy systems. The petition argues the claims are obvious over prior art references Toge, Kumar, Burton, and Kisner. The Board is asked to institute review.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. has filed an IPR petition seeking to invalidate Cleveland Medical Devices' U.S. Patent 11,690,512 covering a wearable sleep diagnostic system. The petition argues that all 20 claims are obvious over a combination of prior‑art references (Ciulla, Orbach, and others) under 35 U.S.C. § 103.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed has filed an IPR petition challenging 12 claims of Cleveland Medical Devices' ’921 patent covering a networked PAP system. The petition argues the claims are obvious over prior art references Toge, Burton, Kumar, and Kisner. It seeks institution of the review.
ResMed Corp. v.Cleveland Medical Devices, Inc.
The PTAB granted institution for ResMed Corp.'s IPR against Cleveland Medical Devices, Inc., finding a reasonable likelihood of prevailing. The Board overcame arguments regarding parallel District Court litigation by applying the Fintiv factors.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully petitioned for institution of its IPR against Cleveland Medical Devices, Inc.'s patent covering CPAP systems. The Board declined discretionary denial, finding that the petitioner adequately demonstrated a reasonable likelihood of prevailing on both 102 and 103 grounds.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Front Line Medical Technologies has filed a post‑grant review petition seeking cancellation of all ten claims of Prytime’s U.S. Patent 11,857,737 covering low‑profile occlusion balloon catheters. The petition relies on multiple prior‑art references to argue obviousness under 35 U.S.C. § 103 and challenges discretionary denial.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
The PTAB institution decision found that the petitioner successfully demonstrated a likelihood of prevailing on its obviousness challenges against all ten claims. The Board adopted broad claim constructions for 'proximal hub' and 'flow valve,' finding they could be separate or sub-elements, which supported the grounds of obviousness over various prior art combinations.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
SHENZHEN ROOT TECHNOLOGY CO., LTD. et al. v.Chiaro Technology Ltd.
Shenzhen Root Technology Co., Ltd. has filed a Petition challenging U.S. Patent No. 11,413,380 held by Chiaro Technology Ltd. The challenge centers on obviousness (Section 103), arguing that the claimed features of the breast pump are combinations of existing prior art references like Chang, Weber, and Guthrie.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition seeking cancellation of claims 1‑7, 10, and 12‑13 of Miracor’s U.S. Patent 11,351,356 covering a catheter‑based LVAD. The petition argues that four prior‑art references disclose every claim limitation, making the claims obvious under §103. The Board has not yet ruled on institution or denial.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories challenged MIRACOR MEDICAL SA's cardiac assist pump patents based on obviousness (35 U.S.C. § 103). The Board adopted the Patent Owner’s broader claim constructions for key terms like 'magneto coupling,' leading to the institution of the IPR.
Avation Medical, Inc. v.EMKinetics, Inc.
EMKinetics seeks Director review of a PTAB decision that found ten claims of its medical‑device patent unpatentable. The owner contends the Board relied on unsupported presumptions of printed publication and admitted untimely rebuttal evidence, violating procedural rules.
Avation Medical, Inc. v.EMKinetics, Inc.
Avation Medical’s IPR against EMKinetics resulted in the PTAB finding claims 1‑10 of U.S. Patent 9,002,477 unpatentable. EMKinetics’ attempt to obtain Director Review was denied as untimely, leaving the Board’s decision intact.
Avation Medical, Inc. v.EMKinetics, Inc.
Avation Medical has filed an IPR petition challenging EMKinetics' 9,002,477 patent covering posterior tibial nerve stimulation for overactive bladder, asserting anticipation and obviousness over multiple prior‑art references.
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB held that all 18 claims of RapidPulse’s ’883 aspiration‑thrombectomy patent are unpatentable after finding them obvious over Teigen, Grey and other prior art.
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB held that all 21 claims of RapidPulse’s ’253 aspiration thrombectomy patent are unpatentable, finding them obvious over Teigen, Grey and other prior art. Penumbra’s petition succeeded, leading to a sweeping invalidation.
Penumbra, Inc. v.RapidPulse, Inc.
Penumbra challenges RapidPulse's patent covering aspiration thrombectomy systems, arguing that the claimed inventions are obvious under 35 U.S.C. §103. The petitioner relies heavily on combining multiple prior art references to demonstrate a motivation for a Person Having Ordinary Skill in the Art (POSA) to make the modifications.
Penumbra, Inc. v.RapidPulse, Inc.
Penumbra successfully petitioned to institute IPR against RapidPulse regarding claims related to aspiration thrombectomy systems. The Board found a reasonable likelihood of obviousness across multiple grounds, including combinations involving Yang and Mullins.
Penumbra, Inc. v.RapidPulse, Inc.
The PTAB rejected Petitioner's obviousness arguments against the '402 patent claims (1-20) related to a thrombectomy/aspiration system. The Board adopted an intrinsic definition of 'predetermined cycle' as fixed timing, finding that prior art combining Mullins and Yang did not teach this limitation.
Solventum Corporation v.M.E.A.C. Engineering Ltd.
Solventum Corporation filed a petition challenging 22 claims of the '534 Patent owned by M.E.A.C. Engineering Ltd., asserting that they are anticipated under 35 U.S.C. § 102. Petitioner argues that the prior art reference, Bitel (WO 03/030966), discloses every element of the claimed negative pressure wound therapy system.
Solventum Corporation v.M.E.A.C. Engineering Ltd.
Solventum Corporation challenged M.E.A.C. Engineering Ltd.'s patent claims related to wound treatment, arguing that the technology was anticipated or obvious in prior art references. The petitioner asserted grounds of anticipation (§ 102) and obviousness (§ 103), citing combinations involving Bitel, Watson, Dolliver, and Argenta.
TikTok Inc. et al. v.Cellspin Soft, Inc.
TikTok challenged a patent owner’s motion to terminate several IPRs over alleged failures to disclose a foreign party‑in‑interest and person‑eligibility issues. The PTAB denied the motion and initiated a sua sponte Director review, staying the IPRs pending further analysis.
Mito Red Light, Inc. v.Joovv, Inc.
Mito Red Light and Joovv settled their IPR dispute over U.S. Patent 11,253,719 B2, leading the PTAB to terminate the proceeding before institution.
Mito Red Light, Inc. v.Joovv, Inc.
Mito Red Light and Joovv have settled their IPR dispute over patent 11253719, filing a joint motion to terminate the proceeding.
Mito Red Light, Inc. v.Joovv, Inc.
Mito Red Light and Joovv have settled their dispute over U.S. Patent 11,253,719 and jointly moved to terminate the IPR. The motion cites settlement and judicial economy as reasons for termination.
Mito Red Light, Inc. v.Joovv, Inc.
Mito Red Light and Joovv have settled their dispute over U.S. Patent 11,253,719 and jointly moved to terminate the IPR, requesting the settlement be kept confidential.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.